Abstract
Endothelial colony‐forming cells (ECFCs) are of significant interest in vascular biomaterials engineering and cell‐based therapies for cardiovascular diseases. Efficient isolation and expansion of ECFCs on polymeric surfaces either in vitro or in situ in the case of implants could significantly advance ECFC‐based therapies. We present a novel bifunctional surface modification strategy combining oriented antibodies and extracellular matrix‐derived peptides to selectively capture ECFCs on surfaces and then mediate firm adhesion, spreading and proliferation. Studies were conducted with anti‐CD309 antibodies and custom RGD peptides, previously shown to respectively enable ECFC capture and clonal expansion. To aid in oriented antibody immobilization on surfaces while modulating antibody‐RGD surface concentrations, Fc‐binding peptides and RGD peptides were co‐immobilized on aminated surfaces using click chemistry, followed by affinity‐mediated antibody immobilization. Bifunctional anti‐CD309 + RGD surfaces selectively captured ECFCs from a mixture with peripheral blood mononuclear cells in dynamic conditions. The presence of RGD peptides significantly enhanced cell spreading and proliferation, leading to additive effects on surface coverage under flow. Proof‐of‐concept studies demonstrated successful adaptation to 3D polystyrene microcarriers, showcasing potential scalability for clinical‐grade cell production. The surface modification scheme provides a versatile and clinically translatable platform for advancing ECFC‐based regenerative therapies.
Funding Information
  • Canadian Institutes of Health Research (CIHR MOP 142285)
  • Canadian Institutes of Health Research (CIHRDV2‐197669)
  • Natural Sciences and Engineering Research Council of Canada (RGPIN‐2020‐05877)
  • Heart and Stroke Foundation of Canada (G‐25‐0041715)

This publication has 47 references indexed in Scilit: